HER2-positive Breast Cancer Clinical Trials in Fuzhou, Fujian
2 recruitingFuzhou, Fujian, China
Showing 1–2 of 2 trials
Recruiting
Phase 2Phase 3
A Study of BL-M07D1 With or Without Pertuzumab Versus Taxane + Trastuzumab and Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer
HER2-positive Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd.120 enrolled30 locationsNCT06891833
Recruiting
Pyrotinib Combined With Trastuzumab for Maintenance Therapy After First-line TH (P) Therapy for HER2+ABC
HER2-positive Breast Cancer
zhangjie60 enrolled1 locationNCT06754059